阿奇霉素治疗小儿上呼吸道肺炎支原体感染临床效果观察

Clinical Observation of Azithromycin in treating Mycoplasma Pneumoniae Infection in Children with Upper Respiratory Tract

目的:探讨阿奇霉素治疗小儿上呼吸道肺炎支原体感染临床效果。方法:收集2016年10月至2017年7月我院收治的100例上呼吸道肺炎支原体感染患儿随机分为两组,阿奇霉素组患儿给予阿奇霉素,克拉霉素组患儿则给予克拉霉素,比较两组患儿相关临床指标、总体治疗效果、相关疾病参数与不良反应。结果:阿奇霉素组患儿退热时间、咳嗽消失时间、细啰音消失时间与哮鸣音消失时间均显著性低于克拉霉素组;痊愈率显著性高于克拉霉素组;治疗后淋巴细胞、IgA、IgE与IgG水平组间比较均显著性高于克拉霉素组,CRP与IL-4水平均显著性低于克拉霉素组,存在显著性差异(P<0.01);两组患儿各类药物不良反应率不存在明显差异(P>0.05)。结论:阿奇霉素治疗小儿上呼吸道肺炎支原体感染的临床效果显著,安全性较高,具有借鉴意义。

Objective： To investigate the clinical effect of azithromycin in the treatment of Mycoplasma pneumoniae infection in children with upper respiratory tract. Methods： 100 cases of upper respiratory tract mycoplasma pneumoniae infection in our hospital from October 2016 to July 2017 were randomly divided into two groups,azithromycin group receiving azithromycin and clarithromycin group receiving clarithromycin,The clinical indicators,the overall treatment effect,the related disease parameters and the adverse reactions of the two groups were compared. Results： The antipyretic time,the disappearance of cough,the disappearance of rales and the disappearance of wheeze in the azithromycin group were significantly lower than those in the clarithromycin group; the cure rate was significantly higher than that in the clarithromycin group; after treatment,the lymphocytes,IgA,IgE and IgG levels were significantly higher than the clarithromycin group,CRP and IL-4 levels were significantly lower than the clarithromycin group,there was a significant difference（P 〈 0.01）; two groups of children There was no significant difference in adverse reaction rate of all kinds of drugs（P〉 0.05）. Conclusion： azithromycin in children with upper respiratory tract infection Mycoplasma pneumoniae clinical effect is significant,higher safety,with reference.